Improving Drug-Like Properties of Insulin and GLP-1 via Molecule Design and Formulation and Improving Diabetes Management with Device & Drug Delivery

Publication date: Available online 30 January 2017
Source:Advanced Drug Delivery Reviews
Author(s): Sergei Pechenov, Himanshu Bhattacharjee, Daniel Yin, Sachin Mittal, Anand Subramony
There is an increased incidence of diabetes worldwide. The discovery of insulin revolutionized the management of diabetes, the revelation of glucagon-like peptide -1 (GLP-1) and introduction of GLP-1 mimetics to clinical practice was another breakthrough. Continued translational research resulted in better understanding of diabetes, which, in combination with cutting-edge biology, chemistry, and pharmaceutical tools, have allowed for the development of safer, more effective and convenient insulins and GLP-1s. Advances in self-administration of insulin and GLP-1 therapies with use of drug-device combination products have improved the outcomes of diabetes management and quality of life for diabetic patients. The synergies of insulin and GLP-1 actions have led to development of devices that can deliver both molecules simultaneously. New chimeric GLP-1-incretins and insulin-GLP-1-incretin molecules are also being developed. The objective of this review is to summarize molecular designs to improve the drug-like properties of insulin and GLP-1 and to highlight the continued advancement of drug-device combinations to improve diabetes management.

Graphical abstract

http://ift.tt/2kKRQKA